– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – –.
– Net revenue rose 27% from prior quarter to $74.6 million –– CIMERLI® net sales increased 50% to $40 million compared to prior quarter –– LOQTORZI™ now approved with launch planned for.
02.08.2023 - – Net revenue rose 81% from prior quarter to $58.7 million –– CIMERLI net sales quadrupled to $26.7 million compared to prior quarter –– UDENYCA autoinjector launched in late May, and YUSIMRY launched in July –– Planned merger with Surface Oncology .
First formal distribution agreement for YUSIMRY™, a biosimilar of Humira®, at $995 per carton (two 40 mg/0.8 mL autoinjectors) representing a discount of.